Skip to main
LBRX

LBRX Stock Forecast & Price Target

LBRX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LB Pharmaceuticals is well positioned in the market with their innovative drug, LB-102, and recent investments show confidence in its potential. With a strong safety profile and potential for use in multiple disorders, the drug could bring significant revenue for the company in the future. The company's plans for expansion into Europe also open up new market opportunities for their product. Overall, LB Pharmaceuticals has a positive outlook for future growth and success.

Bears say

LB Pharmaceuticals is heavily focused on the development of their lead clinical-stage asset, LB-102, to address the growing market for neuropsychiatric disorders and unmet medical needs. While the company has a significant potential for growth, it faces competitive pressures from large pharmaceutical companies and generic antipsychotics. Additionally, the lack of operating history and potential for expenses and difficulties commonly faced by clinical-stage biopharmaceutical companies present a risk for commercial success. LB Pharmaceuticals has a relatively small number of shares outstanding, but the potential offsetting impact of NOLs not being included in assumptions may prove conservative.

LBRX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LB Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LB Pharmaceuticals Inc (LBRX) Forecast

Analysts have given LBRX a Strong Buy based on their latest research and market trends.

According to 5 analysts, LBRX has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LB Pharmaceuticals Inc (LBRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.